Table 2 Subgroup analysis of patients with stapled hemorrhoidopexy and hemorhoidectomy.

Age, mean (SD)

48.9

(13.1)

47.0

(11.6)

0.25^a

48.6

(18.0)

48.6

(14.2)

0.99^a

Sex, n

0.06^b

0.55^b

 Men

58

(48.7%)

43

(36.4%)

14

(58.3%)

15

(50%)

 Women

61

(51.3%)

75

(63.6%)

10

(41.7%)

15

(50%)

BMI, mean (SD)

24.4

(4.29)

24.2

(4.5)

0.68^a

24.0

(3.4)

23.9

(4.2)

0.92^a

HTN, n (%)

18

(15.1%)

22

(18.6%)

0.47^b

5

(20.8%)

7

(23.3%)

0.83^b

DM, n (%)

5

(4.2%)

8

(6.8%)

0.39^b

3

(12.5%)

2

(6.7%)

0.47^b

Hemorrhoid grade, n (%)

0.06^b

0.70^b

 III

37

(31.1%)

26

(22.0%)

5

(20.8%)

5

(16.7%)

 IV

82

(68.9%)

92

(78.0%)

19

(79.2%)

25

(83.3%)

Symptoms, n (%)

 Bleeding

67

(56.3%)

57

(48.3%)

0.19^b

10

(41.7%)

18

(60%)

0.19^b

 Prolapse

90

(75.6%)

98

(83.1%)

0.20^b

14

(58.3%)

21

(70%)

0.38^b

 Pain

55

(46.2%)

54

(45.8%)

0.90^b

15

(62.5%)

21

(70%)

0.57^b

Duration, n (%)

0.94^c

0.98^c

 < 1 month

21

(17.6%)

18

(15.3%)

6

(25%)

8

(26.7%)

 1–12 months

19

(16.0%)

26

(13.6%)

5

(20.8%)

5

(16.7%)

 > 12 months

79

(66.4%)

74

(62.7%)

13

(54.2%)

17

(56.7%)

Previous treatment, n (%)

6

(5.0%)

8

(6.8%)

0.57^b

2

(8.3%)

4

(14.81%)

0.57^b

ASA score, n

0.14^c

0.91^c

 I

53

(44.5%)

65

(55.1%)

10

(41.7%)

14

(46.7%)

 II

66

(55.5%)

52

(44.1%)

14

(58.3%)

15

(50.%)

 III

1

(0.8%)

1

(3.3%)

Anesthesia, n (%)

0.66^b

0.99^b

 General

2

(1.7%)

2

(1.7%)

 Spinal

117

(98.3%)

116

(98.3%)

24

(100%)

30

(100%)

40 mg parecoxib administration times

1.8

(1.2)

1.8

(1.3)

0.78

1.7

(1.6)

1.6

(1.4)

0.87^a